#medication-advancements

#medication-advancements

Incyte tops this list due to its rare combination of commercial scale, cash generation, and pipeline depth. The company posted FY2025 revenue of $5.14 billion, up 21.2% YoY, anchored by Jakafi generating $828.2 million in Q4 2025 alone (+7% YoY) and Opzelura delivering $207.3 million (+28% YoY). With $3.58 billion in cash and 14 pivotal clinical trials underway, Incyte offers an acquirer immediate revenue, margin expansion potential, and a deep oncology pipeline spanning KRASG12D, CDK2 inhibition, and mutCALR.

Many of the medicines on TrumpRx include brand-name drugs that patients can find cheaper elsewhere as generics. For instance, Protonix for heartburn is available for $200 on TrumpRx, but the generic version, pantoprazole, costs less than $30 with a GoodRx coupon.

On that sunny March morning, in a small health center in Lobamba, a rural area of Eswatini, this 32-year-old sex worker has just become one of the first people in the world to receive lenacapavir, a drug that, administered twice a year, offers nearly 100% protection against HIV.

The Food and Drug Administration granted expedited approval to orforglipron, a GLP-1 drug that works like widely used injectable medications to mimic a natural hormone that controls appetite and feelings of fullness.

The condition, called recessive RNU2-2-related neurodevelopmental disorder, is associated with seizures and severe developmental delay in children less than a year-old, in areas such as speech and walking.

If it continues to spread past the demarcation that we usually draw using a skin marker-we say Sharpie, but it's a skin marker-we say that this is spreading. Diagnosis: possible sepsis. Varshavski was not talking to the patient or to nursing staff. He was not even in a hospital. He was speaking into a camera in a two-bedroom apartment on the fifty-sixth floor of a building in Hell's Kitchen, in a makeshift studio where he records videos and his popular podcast.

CES 2026 is here. While the official event begins Tuesday, ZDNET's team of experts has already gotten an early look at some of the most exciting tech stories coming out of Las Vegas.

As the Magerstadt Professor of Cardiovascular Epidemiology, Khan studies the epidemiology of risk for heart failure. Using population-based cohorts and large electronic health record data analyses, she performs mechanistic studies that may enhance risk prediction and identify novel therapeutic agents for the prevention and treatment of cardiovascular disease. Khan and her team have developed a tool to predict risk and prevent cardiovascular disease such as heart failure, stroke, arrhythmia, coronary artery disease and many other conditions.

Before treatment began, participants underwent neuroimaging. Instead of relying on a single modality, the researchers fused structural connectivity (how regions are physically wired) with functional connectivity (how regions co-activate at rest). The goal was not to throw every possible feature at a black box, but to learn a constrained pattern-what the authors call structure-function "covariation"-that carries the most predictive signal for outcome. In other words, the model tries to find the smallest set of connections that meaningfully forecasts symptom change.

Public health consultant Dr Ross Keat said supporting people earlier to make small preventative changes would make "a big difference later on". Some 3,500 people in the north of the island within that age bracket are eligible for the checks. The checks will be carried out by two pre-existing nurses that support GP staff and would not replace GP appointments, Keat explained, adding that the cost would be minimal and absorbed by Ramsey Group Practice.

The cancer was fastacting, and if I'd left it even six months, the outcome could have been much worse,

Between March 2020 and March 2022, over 100 million telemedicine services were delivered to approximately 17 million Australians. The Australian government invested $409 million to make telehealth permanent, whilst the UK announced £600 million for digital health infrastructure in April 2025. Patient adoption is equally impressive: 60% find telemedicine more convenient than in-person appointments, 55% report higher satisfaction with teleconsultations, and 74% of millennials prefer virtual appointments for routine care. These aren't temporary shifts; they represent a fundamental transformation in healthcare delivery.

But these studies typically require large numbers of patients, huge amounts of data, and thorough follow-ups, none of which comes easy or free. The upshot is fewer investigations into scenarios that are clinically important but unlikely to yield a profit for the firms funding them. Accordingly, researchers have been developing an option that uses real-world data from insurers to save patients from falling through the cracks.

EMPAVELI is the first and only approved treatment for C3G and IC-MPGN across pediatric patients 12+, adults, and post-transplant recurrence. That's roughly 5,000 patients in the U.S., with EMPAVELI holding exclusive approval for about two-thirds. Add the European CHMP positive opinion in December 2025, and you have a rare disease franchise with global expansion potential and pricing power that typically commands gross margins north of 90%.

The world of medical practice management is changing faster than ever, driven by two simultaneous forces: escalating patient expectations and crushing administrative complexity. In my years working with healthcare organizations, I've seen these challenges evolve from nuisances into crises. Research by Bain & Company found that 65% of healthcare consumers want more convenient experiences, and 70% want more responsiveness from providers. They want instant answers to routine questions, immediate scheduling access and minimal friction.